A5054490048- Acute Myeloid Leukemia Research
- Epigenetics and DNA Methylation
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Neutropenia and Cancer Infections
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Ferroptosis and cancer prognosis
- Nuclear Structure and Function
- Cancer-related molecular mechanisms research
- Colorectal Cancer Treatments and Studies
- RNA modifications and cancer
- Immunodeficiency and Autoimmune Disorders
- Multiple Myeloma Research and Treatments
- Hemoglobinopathies and Related Disorders
- Retinoids in leukemia and cellular processes
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Cancer-related gene regulation
University of Science and Technology of China
2022-2024
Nanjing Medical University
2024
Jiangsu Province Hospital
2024
<p>Supplementary Figure S3</p>
<p>Supplementary Figure S6</p>
<p>Supplementary Figure S2</p>
<p>Supplementary Figure S8</p>
<p>Supplementary Figure S4</p>
<p>Supplementary Figure S7</p>
<div>Abstract<p>Internal tandem duplication (ITD) in the FMS-like receptor tyrosine kinase-3 (FLT3) is one of most frequent mutations acute myeloid leukemia (AML) and associated with poor prognosis. FLT3-ITD result endoplasmic reticulum (ER) retention constitutive autophosphorylation FLT3. The PR/SET domain 16 (PRDM16) highly expressed patients FLT3-ITD<sup>+</sup> AML, suggesting it might play a role leukemogenesis. Here, we revealed that genetic pharmacologic...
<p>Supplementary Figure S5</p>
<p>Supplementary Figure S1</p>
Introduction We firstly investigate based on 2022 European Leukemia Net (ELN) risk stratification, whether standard-dose cytarabine multiagent sequential chemotherapy (SDMSC) is more beneficial than high-dose (HDAC) monotherapy in consolidation for the survival of adult acute myeloid leukemia (AML) patients. Methods One hundred and eighty-three AML patients with complete remission (CR) were evaluated. Results discussion The 3-year relapse rate was 33.4% HDAC group 50.5% SDMSC ( p =0.066)....
NUAK family kinase 2 (NUAK2) has been identified as an important mediator for tumor progression in multiple malignancies. Nevertheless, its role lung adenocarcinoma (LUAD) remains unclear. Bioinformatic analysis was performed to assess the expression and prognosis of NUAK2 patients with LUAD. The measured LUAD cell lines, loss-of-function experiment conducted. Cell proliferation ability assessed using CCK-8 colony formation assays. Spheroid formation, alkaline phosphatase (AP) staining, tube...
e19007 Background: Extranodal bulky lesions, a significant adverse prognostic factor in lymphoma, commonly denote more aggressive disease course, mandating prompt and intensified treatment strategies. In response, we developed ThisCART19A, non-genetic editing off-the-shelf anti-CD19 CAR T-cell therapy incorporating intracellular retention of membrane proteins, representing novel approach that downregulates surface expression TCRαβ/CD3 complexes. ThisCART19 has exhibited favorable safety...
2502 Background: CART cells have demonstrated remarkable clinical efficacy in treating hematological cancers. However, CRS remains as a major challenge application, with multiple cytokines significantly elevated. IL6 signaling blockade by Tocilizumab has become standard treatment to relieve patients. Our previous studies suggested that CAR T secreting antagonist could effectively maintain at very low levels during CRS. Furthermore, we observed huge quantity of tumor one patient was reduced...
Abstract Internal tandem duplication (ITD) in the FMS-like receptor tyrosine kinase-3 (FLT3) is one of most frequent mutations acute myeloid leukemia (AML) and associated with poor prognosis. FLT3-ITD result endoplasmic reticulum (ER) retention constitutive autophosphorylation FLT3. The PR/SET domain 16 (PRDM16) highly expressed FLT3-ITD+ AML patients, suggesting it might play a role leukemogenesis. Here, we revealed that genetic pharmacological suppression PRDM16 greatly slowed progression...
To retrospectively analyze the incidence of infections in elderly acute myeloid leukemia (AML) patients undergoing induction therapy with venetoclax combined hypomethylating agents and to compare these findings those from receiving standard or low-dose chemotherapy. Medical records 169 (≥60 years old) AML diagnosed via MICM (morphology, immunology, cytogenetics, molecular genetics) at First Affiliated Hospital USTC between June 2019 2022 were reviewed. Patients divided into three groups:...
The BCL-2 inhibitor venetoclax has been widely used in the treatment of acute myeloid leukemia (AML); however, AML patients treated with gradually develop resistance. exportin-1 (XPO1) selinexor can synergistically promote antileukemia activity venetoclax, but mechanism remains unclear.Annexin V/7-aminoactinomycin D assays were to examine effects a combination and (VEN+SEL) on cell lines primary cells. RNA sequencing oxygen consumption rate (OCR) extracellular acidification (ECAR)...
There is great uncertainty in the treatment of elderly patients with acute myeloid leukemia (AML), which leads to challenges decision. The aim this study find more suitable induction therapy and consolidation for AML patients.A total 149 consecutive newly diagnosed (aged ≥60 years) who received chemotherapy our medical center from January 2015 December 2019 were retrospectively analyzed.After first treatment, complete remission/or remission incomplete hematologic recovery (CR/CRi) rates...
Background and Objectives: This study aimed to evaluate whether the addition of hypomethylating agents (HMA) low-intensity chemotherapy can enhance clinical efficacy induction treatment for elderly acute myeloid leukemia (AML) patients who are unsuitable standard therapy. Materials Methods: retrospectively analyzed 117 over 60 years old were initially diagnosed with AML received in Department Hematology Anhui provincial hospital from January 2015 December 2020. Twenty-three excluded,...